Physician

Ami Miten Negandhi, M.D.

According to 2025 Medicare claims, Ami Negandhi, M.D. (NPI: 1235306028) practices medical oncology in the Albany-Schenectady-Troy, NY market, with the plurality of this provider's patient population coming from Albany, NY. This provider's primary affiliated billing organization is NEW YORK ONCOLOGY HEMATOLOGY, P.C. (NPI: 1609863448; TIN: 141799724) and primary practice location at 12206-5012. Negandhi is affiliated with the Trinity Health Integrated Care (ACO ID: A3454), participating under the MSSP model.

Negandhi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 614 traditional Medicare patients, billed 78,582 HCPCS/CPT codes, and received $1,794,853 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,469 prescription claims across 273 beneficiaries totaling $2,131,246 in drug costs, led by Verzenio (Abemaciclib). DME data shows 35 claims. Open Payments data shows 1 records totaling $455. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $31,839 to $1,794,853. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $545,410 and ending at $2,131,246. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $1,058 to $673.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	231	549	$31,839
2016	201	558	$30,029
2017	207	581	$32,404
2018	269	741	$49,436
2019	360	18,233	$420,545
2020	355	29,812	$636,752
2021	328	25,070	$433,787
2022	461	41,908	$728,617
2023	561	76,248	$1,357,116
2024	614	78,582	$1,794,853

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	128	584	$545,410
2016	162	1,020	$754,450
2017	181	1,225	$1,039,550
2018	199	1,312	$1,347,469
2019	160	745	$1,007,289
2020	92	446	$510,855
2021	128	630	$700,765
2022	182	885	$882,644
2023	235	1,128	$1,284,684
2024	273	1,469	$2,131,246

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	69	$32,518
2016	N/R	12	$874
2017	N/R	181	$7,123
2018	N/R	111	$8,486
2019	N/R	97	$3,789
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	53	$1,491
2023	N/R	65	$8,892
2024	N/R	35	$1,073

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	175	278	$92
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	176	286	$12
80053	Blood test, comprehensive group of blood chemicals	349	599	$10
36415	Insertion of needle into vein for collection of blood sample	355	638	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	355	629	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Verzenio	Abemaciclib	49	1,372	$765,149
Ibrance	Palbociclib	26	728	$397,354
Kisqali	Ribociclib Succinate	26	728	$345,292
Brukinsa	Zanubrutinib	12	360	$135,419
Eliquis	Apixaban	54	1,835	$35,090

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	17	$735
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	18	$339

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$455	Daiichi Sankyo Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ami Miten Negandhi, M.D.?

Tedicare shows public-source Medicare data for Ami Miten Negandhi, M.D. (NPI 1235306028), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ami Miten Negandhi, M.D. have ACO affiliation data?

Ami Miten Negandhi, M.D. is shown with ACO affiliation data for Trinity Health Integrated Care (MSSP, ACO ID A3454).

What billing organization is linked to Ami Miten Negandhi, M.D.?

Ami Miten Negandhi, M.D. is linked to NEW YORK ONCOLOGY HEMATOLOGY, P.C. (billing NPI 1609863448) in the available physician profile data.

Does Ami Miten Negandhi, M.D. have Open Payments data?

Ami Miten Negandhi, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.